Terpenoids Against Human Diseases

This book highlights how terpenoids act as biological messengers and can be used as medicine against liver disease, neurodegenerative disease, cancer, infectious disease, cardiovascular disease, and inflammatory diseases. It emphasizes the metabolic engineering approach of terpenoids production and their toxicity.

A Brief History of Terpenoids. Bioengineering Approach on Terpenoids Production. Terpenoids: The Biological Key Molecules. Terpenoids In Treatment Of Liver Disease. Terpenoids In Treatment Of Neurodegenerative Disease. Terpenoids In Treatment Of Immunological Disease. Terpenoids In Cancer Treatment. Terpenoids Against Infectious Diseases. Terpenoids Against Cardiovascular Diseases. Toxicity Of Terpenoids In Human Health.

Dr. Dijendra Nath Roy, PhD, has been currently working as Assistant Professor, Department of Bio Engineering, National Institute of Technology, Agartala, India, since 2013. He received professional bachelor degrees from the Haldia Institute of Technology, West Bengal University of Technology (B.Tech., 2005), and the Doctor of Philosophy from the CSIR-Indian Institute of Chemical Biology [Ph.D. in Bio Engineering, 2011]. Dr. Roy carried out postdoctoral research training at the National University of Singapore, Singapore (2011-2012) and after that, he has been appointed in present position. Dr. Roy is a member of the numerous professional bodies including Indian Science Congress Association, Govt. of India and The Institution of Engineers (India). In addition, Dr. Roy has already earned several project grants from different external funding agencies in India to carry out research on product development, especially drug development. In 2015, he was honoured with prestigious young scientist award from Science and Engineering Research Board, Department of Science and Technology, Govt. of India to implement his research idea into the capacity of laboratory. He is interested to publish this book from CRC Press, Taylor & Francis Group, USA for them, those who are engaged actively in drug development.